Free Trial

Bayer Equity -5%, Credit Spreads Steepen On USD 2.25bn Roundup Herbicide Fine

HEALTHCARE


  • The Philadelphia jury's verdict is the largest in five years of litigation over the herbicide, impacting CEO Bill Anderson's turnaround efforts.
  • The verdict adds to the liability from Bayer's USD 63bn acquisition of Monsanto in 2018,
  • Analysts suggest Bayer might lower its dividend payout or potentially suspend it to fund the expense.
  • Bayer argues the product is safe and plans to appeal the verdict and reduce the "unconstitutionally excessive" damages.
  • While the awarded amount is expected to be reduced on appeal, the high compensatory damages make this move more challenging – BI notes that the USD 250mn is compensatory damages and USD 2bn in punitive damages is within constitutional limits
  • Bayer's Monsanto unit has won 10 of 16 recent Roundup trials, with the next trial scheduled in Delaware.
  • Long-end EUR bonds up to 9bps wider vs. midswaps with more gradual widening at shorter maturities

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.